FDA Approves Niraparib and Abiraterone acetate + Prednisone for BRCA-mutated mCRPC

On August 11, the US Food and Drug Administration (FDA) approved the fixed dose combination of niraparib and abiraterone acetate with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved test.

For more information read the FDA announcement and the Janssen announcement. 

Posted 8/15/2023